The Iowa Dental Board is currently promulgating rules to implement HF 2377, otherwise known as the "Opioid Bill," which was signed into law in May 2018. The timeline for implementation of these rules has been revised, and they are now tentatively slated to go into effect on May 29, 2019.
The Iowa Dental Board is currently promulgating rules to implement HF 2377, otherwise known as the "Opioid Bill," which was signed into law in May 2018. The timeline for implementation of these rules has been revised, and they are now tentatively slated to go into effect on May 29, 2019. Key provisions include:
- Mandatory registration to the Prescription Monitoring Program (PMP) at the time of initial registration or renewal of a Controlled Substance Act Registration (CSAR) with the Iowa Board of Pharmacy.
- Mandatory use of the PMP. Queries shall be performed within 48 hours prior to an opioid prescription being issued or dispensed and shall be done for every patient each time an opioid prescription is issued or dispensed.
A new provision in 650 Iowa Administrative Code - Chapter 30, which specifically establishes grounds for discipline related to prescribing opioids in amounts exceeding what would be prescribed by a reasonably-prudent prescribing practitioner engaged in a similar practice.
Mandatory reporting to the PMP within one business day when a controlled substance is dispensed* to a patient. Please note: Administration* of a drug does not need to be reported to the PMP.
- Dispense: To provide a prescription drug to a patient for self-use outside of the provider's practice location.
- Administration: To provide or apply a prescription drug to a patient for immediate use within the provider's practice location.
Mandatory one hour of continuing education for any dentists who prescribe opioids - to be first reported to the Board during the 2020 renewal, and every renewal period thereafter. Dentists who do not prescribe opioids are exempt from this requirement. This training shall include guidelines for prescribing opioids, including recommendations on limitations of dosages and the length of prescriptions, risk factors for abuse, and non-opioid and non-pharmacologic therapy options. If the continuing education did not cover the United States Centers for Disease Control and Prevention guideline for prescribing opioids for chronic pain, the licensee shall read the guideline prior to license renewal. Please note: IDA's IDEAS19's offers a course
that will fulfill this requirement.
Mandatory electronic prescribing for all prescriptions, including controlled substances, will go into effect on January 1, 2020.